PEAK: a randomized, multicenter phase II study of panitumumab plus modified fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) or bevacizumab plus mFOLFOX6 in patients with previously untreated, unresectable, wild-type KRAS exon 2 metastatic color - Wikidata - awgldk - TriplyDB

PEAK: a randomized, multicenter phase II study of panitumumab plus modified fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) or bevacizumab plus mFOLFOX6 in patients with previously untreated, unresectable, wild-type KRAS exon 2 metastatic color

PEAK: a randomized, multicenter phase II study of panitumumab plus modified fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) or bevacizumab plus mFOLFOX6 in patients with previously untreated, unresectable, wild-type KRAS exon 2 metastatic color

http://www.wikidata.org/entity/Q34660907

about

Treatment of Metastatic Colorectal Cancer: Standard of Care and Future Perspectives Genomic diversity of colorectal cancer: Changing landscape and emerging targets Molecular Subtypes and Personalized Therapy in Metastatic Colorectal Cancer Advances of Targeted Therapy in Treatment of Unresectable Metastatic Colorectal Cancer Advances in targeted and immunobased therapies for colorectal cancer in the genomic era Profile of panitumumab as first-line treatment in patients with wild-type KRAS metastatic colorectal cancer Adjuvant chemotherapy for resected colorectal cancer metastases: Literature review and meta-analysis Tropomyosin-related kinase B/brain derived-neurotrophic factor signaling pathway as a potential therapeutic target for colorectal cancer A Comprehensive Review of Clinical Trials on EGFR Inhibitors Such as Cetuximab and Panitumumab as Monotherapy and in Combination for Treatment of Metastatic Colorectal Cancer A Systematic Review and Network Meta-Analysis of Biologic Agents in the First Line Setting for Advanced Colorectal Cancer Precision medicine in colorectal cancer: the molecular profile alters treatment strategies New findings on primary and acquired resistance to anti-EGFR therapy in metastatic colorectal cancer: do all roads lead to RAS?Management of colorectal cancer Treatment of metastatic colorectal cancer: focus on panitumumab ESMO - Magnitude of Clinical Benefit Scale V.1.0 questions and answers Therapeutic options for peritoneal metastasis arising from colorectal cancer Role of targeted therapy in metastatic colorectal cancer Molecular Diagnostics for Precision Medicine in Colorectal Cancer: Current Status and Future Perspective Therapeutic value of EGFR inhibition in CRC and NSCLC: 15 years of clinical evidence Mechanisms of resistance to anti-EGFR therapy in colorectal cancer RAS and BRAF in metastatic colorectal cancer management Mechanisms of resistance to anti-epidermal growth factor receptor inhibitors in metastatic colorectal cancer Role of Deficient Mismatch Repair in the Personalized Management of Colorectal Cancer Panitumumab in Metastatic Colorectal Cancer: The Importance of Tumour RAS Status Is conversion therapy possible in stage IV gastric cancer: the proposal of new biological categories of classification Extended RAS testing in metastatic colorectal cancer-Refining the predictive molecular biomarkers Translating genomic profiling to gastrointestinal cancer treatment.Targeted therapies in metastatic colorectal cancer: a systematic review and assessment of currently available data RAS Mutations Beyond KRAS Exon 2: A Review and Discussion of Clinical Trial Data.A multi-institutional feasibility study of S-1/oxaliplatin plus bevacizumab in patients with advanced/metastatic colorectal cancer: the HiSCO-02 prospective phase II study.Recent Advances in Targeting the EGFR Signaling Pathway for the Treatment of Metastatic Colorectal Cancer Reply to S. Zhang, L. Fornaro et al, and H.J. Lee et al Primary and acquired resistance to biologic therapies in gastrointestinal cancers.Metastatic colorectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.Expanded RAS: refining the patient population Correlation of extended RAS and PIK3CA gene mutation status with outcomes from the phase III AGITG MAX STUDY involving capecitabine alone or in combination with bevacizumab plus or minus mitomycin C in advanced colorectal cancer Japanese Society of Medical Oncology Clinical Guidelines: RAS (KRAS/NRAS) mutation testing in colorectal cancer patients A retrospective observational study of clinicopathological features of KRAS, NRAS, BRAF and PIK3CA mutations in Japanese patients with metastatic colorectal cancer.Consensus statement: the 16th Annual Western Canadian Gastrointestinal Cancer Consensus Conference; Saskatoon, Saskatchewan; September 5-6, 2014 Extended RAS and BRAF Mutation Analysis Using Next-Generation Sequencing.

P2860

Q26738801-682FB639-64AB-4836-A7E2-77ABAF67B9F9 Q26739052-7766D991-82C4-4A7C-ABD3-3B8F9772951E Q26747329-9AB82E65-6FDF-4A67-9B50-A0A6A66BFA19 Q26748924-E7386655-4034-4997-B7FD-700E0D2AD8CA Q26751344-C8F1A41A-6729-4447-8703-D2FE6C783867 Q26771952-7AEA0B0E-4EBF-4773-A6BA-2D98950FC458 Q26774704-7CCB4D56-3255-4FCC-B8A7-72F4118EB110 Q26774713-1B6E3562-F1B3-4AD4-9E26-557A5A40CE33 Q26775711-4A0FEB99-B97D-47B4-9A3B-6A60BC6A4CE2 Q26782245-76681714-295D-4FB5-A3A7-8A31D4731957 Q26795558-0018E9D6-0704-44AA-9862-9AF4D7379FC5 Q26796348-0E46E79D-C32E-45BD-B076-50B436860F14 Q26823550-D5206A84-DF44-4E7E-B007-3006EEE0210C Q27022954-0ED2A261-555E-4C74-AE77-54325B5C1A1E Q28066272-EBCC70FF-7CE9-4641-9252-1DE73F24B66A Q28067123-223AAA38-02AD-4E8A-96A4-30A07E5EE475 Q28068817-57683B84-7906-4269-A835-09EB165FA05A Q28070038-4C152A66-74A3-4913-8525-B2E5ED77073F Q28071772-A07E9C7A-4645-4F73-B32B-4BA66668BB05 Q28074073-6B5C2AA6-429B-472E-98E4-FD957B6319F4 Q28074175-D97F91B0-CD18-4AA2-84AE-ABC62C86C2CA Q28076490-F992C341-5620-4925-82D6-8483A59405A8 Q28080176-900EB09B-D34C-450C-ADDB-206BA8086CB6 Q28082816-03E4B6F3-25DD-4DBD-AAB5-54F1EB6C7257 Q28084888-25D6B174-1E26-42FB-893A-728E2E904072 Q28087333-39627B32-9A4B-4D7A-9CF3-22843C0124F0 Q30239109-9C6182A1-314A-42F7-8F7A-BFF32BEC506C Q30862367-897C73F6-C136-405A-82D6-7968D6E12885 Q30967175-8004BAE5-095C-4EAE-9544-82F2F6FFCE37 Q33436476-D0C90B54-654A-485A-83C1-6FCDB73B861D Q33624491-7A17EBD5-8E64-4E09-80A3-7AE15A4342ED Q33816865-EF8F0807-D6B3-4E7A-A0EB-02180E63B9BD Q33895573-9D540BB4-0CAE-427E-98BC-DB379263F5AB Q34664272-7DB1B1BA-06E9-49DE-B441-2E5A4B64A98A Q35102475-1857C460-D240-4CB0-825A-7BA70F35A9B6 Q35198335-76023CD8-BC9C-4C59-A1D2-63C09231B791 Q35223898-B583D580-613B-4B3E-A447-853568A739F1 Q35368335-5F47674F-7E49-4D22-8A9B-03FE48893C70 Q35445092-33330C55-CADF-4B79-BDAA-051FD6A61FEB Q35587176-1D4EFD90-3B92-495C-BB28-72B2EDA58A3B

P2860

PEAK: a randomized, multicenter phase II study of panitumumab plus modified fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) or bevacizumab plus mFOLFOX6 in patients with previously untreated, unresectable, wild-type KRAS exon 2 metastatic color

http://www.wikidata.org/entity/Q34660907

description

2014 nî lūn-bûn

@nan

2014 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի մարտին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

PEAK: a randomized, multicente ...... e KRAS exon 2 metastatic color

@ast

PEAK: a randomized, multicente ...... e KRAS exon 2 metastatic color

@en

PEAK: a randomized, multicente ...... e KRAS exon 2 metastatic color

@nl

type

label

PEAK: a randomized, multicente ...... e KRAS exon 2 metastatic color

@ast

PEAK: a randomized, multicente ...... e KRAS exon 2 metastatic color

@en

PEAK: a randomized, multicente ...... e KRAS exon 2 metastatic color

@nl

prefLabel

PEAK: a randomized, multicente ...... e KRAS exon 2 metastatic color

@ast

PEAK: a randomized, multicente ...... e KRAS exon 2 metastatic color

@en

PEAK: a randomized, multicente ...... e KRAS exon 2 metastatic color

@nl

P1433

Q34660907-BA304FD7-A6AE-4E20-8EB9-0ECFFD61866B

P1476

Q34660907-EC47DB06-DB88-4011-9D23-E1B6E36BDE99

P2093

Q34660907-010CD45F-FB28-401C-9469-C5940E69F0A5

Q34660907-27A63D06-2B57-45DD-9EF8-54699B537EF1

Q34660907-37747C84-E2D1-4C23-B4F0-3C602CC5B696

Q34660907-5FE9737C-2370-4CEC-8AEB-FABA81608239

Q34660907-919A7ABC-39E1-4872-B38B-AE653217DF2C

Q34660907-9A119E1B-FA59-47F9-97CD-1DD885EC04CB

Q34660907-B5B275FA-D79F-4C3D-8212-0457CC8B11BF

Q34660907-C73941FF-D895-4407-8F90-AF7ADA20C209

Q34660907-E7D5588C-A8E0-4EDA-8C49-3889693260C3

P304

Q34660907-3F0E3A9B-BE09-411C-9682-95B7761818D5

P31

Q34660907-91053341-B3AB-4B82-B547-F9F00F46165D

P356

Q34660907-F830BD50-FF92-485D-8494-4AE11B7C5EB4

P407

Q34660907-188909E1-A9E2-4446-B019-865D077F21CE

P433

Q34660907-00700ED0-C5A1-4C78-8486-5EA266CADE35

P478

Q34660907-E43DE8E4-60A2-4138-8D09-04808EDA2949

P577

Q34660907-624AB7E0-333B-4398-A541-90D07DBA35BB

P5875

Q34660907-642BFE89-E54E-4531-8EA0-AB416FDDD7CE

P698

Q34660907-CAC8A055-951E-4B1F-9994-744425F10933

P921

Q34660907-AA7C1800-A6D9-455D-9E54-548294257D75

Q34660907-B8E066CA-D51F-47F4-8BB4-E548C3A5715F

Q34660907-E5492216-640C-49D0-9655-8F65A7E7FA8B

P356

JCO.2013.53.2473

P1433

Journal of Clinical Oncology

P1476

PEAK: a randomized, multicente ...... e KRAS exon 2 metastatic color

@en

P2093

Fernando Rivera

http://www.w3.org/2001/XMLSchema#string

Gianpiero Fasola

http://www.w3.org/2001/XMLSchema#string

Hua Yu

http://www.w3.org/2001/XMLSchema#string

J Randolph Hecht

http://www.w3.org/2001/XMLSchema#string

Jean-Luc Canon

http://www.w3.org/2001/XMLSchema#string

Kelly S Oliner

http://www.w3.org/2001/XMLSchema#string

Lee S Schwartzberg

http://www.w3.org/2001/XMLSchema#string

Meinolf Karthaus

http://www.w3.org/2001/XMLSchema#string

William Y Go

http://www.w3.org/2001/XMLSchema#string

P304

2240-2247

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JCO.2013.53.2473

http://www.w3.org/2001/XMLSchema#string

P407

P433

21

http://www.w3.org/2001/XMLSchema#string

P478

32

http://www.w3.org/2001/XMLSchema#string

P577

2014-03-31T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

261256411

http://www.w3.org/2001/XMLSchema#string

P698

24687833

http://www.w3.org/2001/XMLSchema#string

P921

multicenter trial